Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Home/Biomarker

EGFR uncommon mutations (G719X / S768I / L861Q)

Gene: EGFR · Type: mutation

Indications: Non-small cell lung cancer

Sensitivity Resistance CIViC Context

Linked CIViC Profile: EGFR MUTATION

Evidence Level Distribution

Level A: 2Level B: 14Level C: 1

Level	Type	Direction	Significance	Disease	Drugs	Rating
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	5
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	5
B	Prognostic	Supports	Better Outcome	Lung Adenocarcinoma		4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	4
C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	4
B	Predictive	Supports	Sensitivity/Response	Peritoneal Mesothelioma	Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	4
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Datopotamab Deruxtecan Regimen	4
A	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Datopotamab Deruxtecan	4
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	3
B	Prognostic	Supports	Better Outcome	Lung Adenocarcinoma		3
B	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	3
B	Predictive	Supports	Sensitivity/Response	Lung Cancer	Gefitinib	2
B	Predictive	Supports	Sensitivity/Response	Lung Cancer	Erlotinib	2